Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lastacaft vs Pataday in Acute Allergic Conjunctivitis
NCT01732757Phase 4Completed
- Sponsor
- Allergan
- Start
- Nov 2012
- Primary completion
- Dec 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of alcaftadine in allergic conjunctivitis (AC) (3 arms), sponsored by Allergan. Primary endpoint: Ocular Itching Evaluated by the Subject. Started Nov 2012; status: completed.
02
Drugs
alcaftadine
03
Conditions
allergic conjunctivitis (AC)
Beyond the preview
Go deeper on NCT01732757.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01732757.